|
First-line pembrolizumab (pembro) monotherapy in advanced non-clear cell renal cell carcinoma (nccRCC): Updated follow-up for KEYNOTE-427 cohort B. |
|
|
Honoraria - Amgen; Astellas Pharma; Bristol-Myers Squibb; Pfizer |
Consulting or Advisory Role - Alteogen; Bristol-Myers Squibb; Pfizer; Sanofi/Aventis |
Research Funding - AstraZeneca/MedImmune (Inst); Bayer Schering Pharma (Inst); Bristol-Myers Squibb (Inst); Janssen (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst); Seagen (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
Vsevolod Borisovich Matveev |
Honoraria - Astellas Pharma; Bayer; Bristol-Myers Squibb; Janssen |
Consulting or Advisory Role - Astellas Pharma; Bayer; Bristol-Myers Squibb; Janssen |
|
|
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; Merck; Pfizer |
Travel, Accommodations, Expenses - Astellas Pharma; Pfizer |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Amgen; Astellas Pharma; Bayer; Janssen; Sanofi |
Consulting or Advisory Role - Amgen; Astellas Amgen BioPharama; Bayer; Janssen; Sanofi |
Speakers' Bureau - Amgen; Astellas Pharma; Bayer; Sanofi |
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Sanofi (Inst) |
Expert Testimony - Amgen; Astellas Pharma; Bayer; Sanofi |
Travel, Accommodations, Expenses - Bayer; Sanofi |
|
|
Research Funding - Ipsen (Inst); Pfizer (Inst) |
|
|
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Ferring; Janssen; Merck; Pfizer; Sanofi |
Speakers' Bureau - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Ferring; Janssen; Merck; Pfizer; Sanofi |
Research Funding - Astellas Pharma; AstraZeneca; Bavarian Nordic; Bayer; Bristol-Myers Squibb; ICON Clinical Research; Janssen; Merck; Pfizer; Sanofi |
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Janssen; MSD; Pfizer; Sanofi |
|
|
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests - Merck |
Honoraria - Bristol-Myers Squibb; Eisai; Ipsen; Novartis; Pfizer |
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; Ipsen; Novartis; Pfizer |
Research Funding - Merck (Inst); Pfizer (Inst) |
Travel, Accommodations, Expenses - Novartis; Pfizer |
|
|
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Ipsen; Janssen Oncology; Lilly; MSD Oncology; Novartis; Pfizer; Pierre Fabre; Roche/Genentech; Sanofi; Sanofi |
Research Funding - Janssen Oncology (Inst) |
Travel, Accommodations, Expenses - AstraZeneca Spain; Bristol-Myers Squibb; Pfizer; Roche |
|
|
|
|
|
|
Stock and Other Ownership Interests - MSD |
|
|
Employment - Karyopharm Therapeutics; Merck |
Leadership - Karyopharm Therapeutics; Merck |
Stock and Other Ownership Interests - Karyopharm Therapeutics; Merck |
Honoraria - Karyopharm Therapeutics; Merck |
Research Funding - Karyopharm Therapeutics; Merck |
Travel, Accommodations, Expenses - Karyopharm Therapeutics; Merck |
|
|
Consulting or Advisory Role - alkermes; Array BioPharma; Bristol-Myers Squibb; EMD Serono; exelixis; Genentech/Roche; Jounce Therapeutics; Lilly; Merck; Novartis; Peloton Therapeutics; Pfizer |
Research Funding - alkermes (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); Merck (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Prometheus (Inst) |
Other Relationship - Beth Israel Deaconess Medical Center |
(OPTIONAL) Uncompensated Relationships - AVEO; X4 Pharma |
|
|
|
Consulting or Advisory Role - Agenus; Array BioPharma; Arrowhead Pharmaceuticals; Aveo; Bristol-Myers Squibb; Cota Healthcare; Eisai; Exelixis; Fathom Biotechnology; Genentech; Glactone Pharma; Immunocore; Iovance Biotherapeutics; Leads Biolabs; Merck; Neoleukin Therapeutics; Novartis; Oncolys BioPharma; Pfizer; Pneuma Respiratory; Pyxis; Surface Oncology; Werewolf Pharma; X4 Pharma |
Research Funding - Bristol-Myers Squibb (Inst) |